Label Changes for:
Reclast (zoledronic acid) Injection
Changes have been made to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011 and August 2011
- Reclast is contraindicated in patients with creatinine clearance < 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions (5.3)]
WARNINGS AND PRECAUTIONS
- Reclast is contraindicated in patients with creatinine clearance <35 mL/min and in those with evidence of acute renal impairment. [See Contraindications (4.2)]. If history or physical signs suggest dehydration, Reclast therapy should be withheld until normovolemic status has been achieved. [See Post-marketing Experience (6.2)]….
Reclast can cause serious side effects including:
Severe kidney problems.
Severe kidney problems may happen when you take Reclast. Severe kidney problems may lead to hospitalization or kidney dialysis and can be life-threatening. Your risk of kidney problems is higher if you:
- already have kidney problems
- take a diuretic or “water pill”
- do not have enough water in your body (dehydrated) before or after you receive Reclast
- are of advanced age since the risk increases as you get older
- take any medicines known to harm your kidneys
You should drink at least 2 glasses of fluid within a few hours before receiving Reclast to reduce the risk of kidney problems.
- osteonecrosis of the jaw, ocular adverse events, and hypotension